Literature DB >> 25970054

Mutation-specific T cells for immunotherapy of gliomas.

Cornelis J M Melief.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25970054     DOI: 10.1056/NEJMcibr1501818

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

Review 2.  Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.

Authors:  Geraldine OʼSullivan Coyne; Alice Chen; Shivaani Kummar
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

3.  Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.

Authors:  Tana A Omokoko; Uli Luxemburger; Shaheer Bardissi; Petra Simon; Magdalena Utsch; Andrea Breitkreuz; Özlem Türeci; Ugur Sahin
Journal:  J Immunol Res       Date:  2016-01-05       Impact factor: 4.818

Review 4.  Personalized cancer neoantigen vaccines come of age.

Authors:  Yanhong Chu; Qin Liu; Jia Wei; Baorui Liu
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

Review 5.  Cancer vaccines as promising immuno-therapeutics: platforms and current progress.

Authors:  Jian Liu; Minyang Fu; Manni Wang; Dandan Wan; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-03-18       Impact factor: 17.388

Review 6.  Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.

Authors:  Xiaoting Zhou; Yanghong Ni; Xiao Liang; Yi Lin; Biao An; Xiang He; Xia Zhao
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.